Patrick G Enright bought $7.2M of BioAge Labs (BIOA)
Executed Sep 27 2024, disclosed Sep 27 2024, the same day.
Over the 21 trading sessions from the disclosed entry session (Sep 27 2024), the stock returned +24.7% (delay-adjusted); from the execution session (Sep 27 2024), +24.7%. Derived: entry at the session's open, exit at the close 20 sessions later.
Patrick G Enright (Director) filed 3 Form 4 reports in the trailing twelve months (3 purchases, 0 sales), most often in Vera Therapeutics, Inc. (VERA). Across 3 priced purchase filings, the average 21-session return was +18.6% from execution and +20.1% from disclosure (delay-adjusted; derived). The largest single filing was $18.3M of MANE (1,075,000 sh across 2 lots, as filed), executed Feb 5.
Healthcare · BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→